Stock RGIN REGENICIN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Regenicin, Inc.

Equities

RGIN

US75887Q1022

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 10:16:10 2024-04-11 am EDT 		5-day change 1st Jan Change
0.005 USD +4,900.00% Intraday chart for Regenicin, Inc. 0.00% +499,900.00%
2023 Regenicin, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
2023 Regenicin, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022 CI

Valuation

Fiscal Period: Settembre 2017 2018 2019 2020 2021 2022
Capitalization 1 9.209 6.001 2.916 1.842 3.07 0.4911
Enterprise Value (EV) 1 9.425 6.35 3.365 2.416 3.668 1.119
P/E ratio -6 x -9.53 x -1.9 x -2.92 x -2 x -0.71 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA - - - - - -
EV / FCF 186 x 83.6 x 18 x -252 x 12 x 5.28 x
FCF Yield 0.54% 1.2% 5.54% -0.4% 8.31% 18.9%
Price to Book -3.77 x -2 x -0.78 x -0.43 x -0.59 x -0.09 x
Nbr of stocks (in thousands) 153,483 153,483 153,483 153,483 153,483 153,483
Reference price 2 0.0600 0.0391 0.0190 0.0120 0.0200 0.003200
Announcement Date 1/16/18 1/15/19 1/14/20 1/13/21 1/13/22 1/13/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2017 2018 2019 2020 2021 2022
Net sales - - - - - -
EBITDA - - - - - -
EBIT 1 -0.9611 -0.5403 -0.7366 -0.6637 -0.8424 -0.6012
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -0.9739 -0.5591 -0.7585 -0.5596 -0.8771 -0.6393
Net income 1 -0.9739 -0.5591 -0.7585 -0.5596 -0.8771 -0.6393
Net margin - - - - - -
EPS 2 -0.0100 -0.004103 -0.0100 -0.004108 -0.0100 -0.004510
Free Cash Flow 1 0.0506 0.0759 0.1865 -0.009582 0.3048 0.2117
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 1/16/18 1/15/19 1/14/20 1/13/21 1/13/22 1/13/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2017 2018 2019 2020 2021 2022
Net Debt 1 0.22 0.35 0.45 0.57 0.6 0.63
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 0.05 0.08 0.19 -0.01 0.3 0.21
ROE (net income / shareholders' equity) 49.8% 20.5% 22.5% 14% 18.6% 12.1%
ROA (Net income/ Total Assets) -268% -468% -1,491% -8,774% -12,034% -3,738%
Assets 1 0.3629 0.1194 0.0509 0.006378 0.007289 0.0171
Book Value Per Share 2 -0.0200 -0.0200 -0.0200 -0.0300 -0.0300 -0.0400
Cash Flow per Share 2 0 0 0 0 0 0
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 1/16/18 1/15/19 1/14/20 1/13/21 1/13/22 1/13/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
REGENICIN, INC. Stock Regenicin, Inc.
+499,900.00% 767K
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.63% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.62% 95.28B
ARGENX SE Stock argenx SE
+1.46% 22.15B
BIONTECH SE Stock BioNTech SE
-16.67% 21.02B
GENMAB A/S Stock Genmab A/S
-8.58% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.74% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.41% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.57% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RGIN Stock
  4. Financials Regenicin, Inc.